SS-Inclisiran sodium is an innovative therapeutic agent employing small interfering RNA (siRNA) technology for combating hypercholesterolemia. Its mechanism of action involves suppressing hepatic production of proprotein convertase subtilisin/kexin type 9 (PCSK9) messenger RNA, resulting in diminished PCSK9 protein concentration and consequent reduction of LDL cholesterol levels in afflicted individuals.
Chemical Structure:
